Baseline characteristics at diagnosis of 1079 patients with MF and their corresponding controls
| Variables . | MF, N = 1079 . | Controls, N = 5395 . |
|---|---|---|
| Demographics | ||
| Age, median (Q1-Q3), y | 72 (63.2-78.8) | 72 (63.2-78.9) |
| Female | 465 (43.1) | 2325 (43.1) |
| Medical history | ||
| Hypertension | 383 (35.5) | 1651 (30.6) |
| Diabetes mellitus | 123 (11.4) | 551 (10.2) |
| Atrial fibrillation | 112 (10.4) | 572 (10.6) |
| Congestive heart failure | 93 (8.6) | 339 (6.3) |
| COPD | 55 (5.1) | 220 (4.1) |
| Chronic renal failure | 39 (3.6) | 100 (1.9) |
| Obesitas | 24 (2.2) | 137 (2.5) |
| Liver disease | 27 (2.5) | 59 (1.1) |
| Non-hematological cancer | 245 (22.7) | 1022 (18.9) |
| Hematological cancer | 51 (4.7) | 75 (1.4) |
| Previous arterial event | ||
| Any arterial event | 268 (24.8) | 1035 (19.2) |
| Ischemic stroke | 88 (8.2) | 378 (7.0) |
| Ischemic heart disease | 188 (17.4) | 762 (14.1) |
| PAD | 19 (1.8) | 26 (0.48) |
| Previous venous event | ||
| Any venous thrombosis | 86 (8.0) | 200 (3.7) |
| Pulmonary embolism | 36 (3.3) | 102 (1.9) |
| Deep venous thrombosis | 37 (3.4) | 116 (2.2) |
| Splanchnic vein thrombosis | 19 (1.8) | 2 (0.037) |
| Cerebral venous thrombosis | 1 (0.093) | 1 (0.019) |
| Previous major bleeding | ||
| Any major bleeding | 92 (8.5) | 301 (5.6) |
| Cerebral hemorrhage | 14 (1.3) | 59 (1.1) |
| Gastrointestinal bleeding | 80 (7.4) | 247 (4.6) |
| Antithrombotic treatment | ||
| Any antithrombotic treatment | 516 (47.8) | 1 613 (29.9) |
| Antiplatelet agents | 405 (37.5) | 1 149 (21.3) |
| Direct oral anticoagulants | 48 (4.4) | 196 (3.6) |
| Vitamin K antagonist | 59 (5.5) | 279 (5.2) |
| Low-molecular-weight heparin | 42 (3.9) | 77 (1.4) |
| Variables . | MF, N = 1079 . | Controls, N = 5395 . |
|---|---|---|
| Demographics | ||
| Age, median (Q1-Q3), y | 72 (63.2-78.8) | 72 (63.2-78.9) |
| Female | 465 (43.1) | 2325 (43.1) |
| Medical history | ||
| Hypertension | 383 (35.5) | 1651 (30.6) |
| Diabetes mellitus | 123 (11.4) | 551 (10.2) |
| Atrial fibrillation | 112 (10.4) | 572 (10.6) |
| Congestive heart failure | 93 (8.6) | 339 (6.3) |
| COPD | 55 (5.1) | 220 (4.1) |
| Chronic renal failure | 39 (3.6) | 100 (1.9) |
| Obesitas | 24 (2.2) | 137 (2.5) |
| Liver disease | 27 (2.5) | 59 (1.1) |
| Non-hematological cancer | 245 (22.7) | 1022 (18.9) |
| Hematological cancer | 51 (4.7) | 75 (1.4) |
| Previous arterial event | ||
| Any arterial event | 268 (24.8) | 1035 (19.2) |
| Ischemic stroke | 88 (8.2) | 378 (7.0) |
| Ischemic heart disease | 188 (17.4) | 762 (14.1) |
| PAD | 19 (1.8) | 26 (0.48) |
| Previous venous event | ||
| Any venous thrombosis | 86 (8.0) | 200 (3.7) |
| Pulmonary embolism | 36 (3.3) | 102 (1.9) |
| Deep venous thrombosis | 37 (3.4) | 116 (2.2) |
| Splanchnic vein thrombosis | 19 (1.8) | 2 (0.037) |
| Cerebral venous thrombosis | 1 (0.093) | 1 (0.019) |
| Previous major bleeding | ||
| Any major bleeding | 92 (8.5) | 301 (5.6) |
| Cerebral hemorrhage | 14 (1.3) | 59 (1.1) |
| Gastrointestinal bleeding | 80 (7.4) | 247 (4.6) |
| Antithrombotic treatment | ||
| Any antithrombotic treatment | 516 (47.8) | 1 613 (29.9) |
| Antiplatelet agents | 405 (37.5) | 1 149 (21.3) |
| Direct oral anticoagulants | 48 (4.4) | 196 (3.6) |
| Vitamin K antagonist | 59 (5.5) | 279 (5.2) |
| Low-molecular-weight heparin | 42 (3.9) | 77 (1.4) |
Data are presented as n (%), unless otherwise specified.
COPD, chronic pulmonary obstructive disease; PAD, peripheral arterial disease; Q1, first quartile; Q3, third quartile.